Experienced in Splenic Neoplasm

Dr. Elizabeth Buchbinder

Hematology | Oncology
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Splenic Neoplasm
Dana-Farber Cancer Institute, Inc.
450 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Buchbinder is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Buchbinder is rated as an Experienced provider by MediFind in the treatment of Splenic Neoplasm. Her top areas of expertise are Melanoma, Vulvar Cancer, Primitive Neuroectodermal Tumor (PNET), Posterior Fossa Tumor, and Tissue Biopsy.

Her clinical research consists of co-authoring 96 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Splenic Neoplasm.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

DANA-FARBER CANCER INSTITUTE, INC.
450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Buchbinder has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
Enrollment Status: Recruiting
Publish Date: May 13, 2024
Intervention Type: Biological, Drug
Study Drugs: SX-682, Pembrolizumab
Study Phase: Phase 1
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination With Dabrafenib for the Treatment of Advanced Solid Tumors With MAPK Pathway Mutations
Enrollment Status: Suspended
Publish Date: September 03, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Exploring the Utility of a Novel BRAF Test in Patients With Melanoma
Enrollment Status: Completed
Publish Date: September 04, 2024
A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition
A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition
Enrollment Status: Completed
Publish Date: July 31, 2024
Intervention Type: Drug
Study Drugs: MCS110, Dabrafenib, Trametinib
Study Phase: Phase 1/Phase 2
A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Enrollment Status: Completed
Publish Date: July 17, 2024
Intervention Type: Drug
Study Drugs: LY3022855, Vemurafenib, Cobimetinib
Study Phase: Phase 1/Phase 2
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: BVD-523
Study Phase: Phase 2
Copy of A Phase II Trial of Pembrolizumab (Anti PD-1) Therapy Combined With Sargramostim (GM-CSF) in Unresectable or Metastatic Melanoma
Copy of A Phase II Trial of Pembrolizumab (Anti PD-1) Therapy Combined With Sargramostim (GM-CSF) in Unresectable or Metastatic Melanoma
Enrollment Status: Withdrawn
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drugs: Sargramostim, Pembrolizumab
Study Phase: Phase 2
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Enrollment Status: Withdrawn
Publish Date: February 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: August 24, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

96 Total Publications

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.
Journal: Journal of Cancer
Published: May 20, 2025
Similar Doctors
Advanced in Splenic Neoplasm
Dr. Adam J. Olszewski
Hematology Oncology | Hematology | Oncology
Advanced in Splenic Neoplasm
Dr. Adam J. Olszewski
Hematology Oncology | Hematology | Oncology

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (39.5 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Adam Olszewski is a Hematologist Oncology specialist and a Hematologist in Providence, Rhode Island. Dr. Olszewski is rated as an Elite provider by MediFind in the treatment of Splenic Neoplasm. His top areas of expertise are B-Cell Lymphoma, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma, Splenectomy, and Bone Marrow Aspiration.

Advanced in Splenic Neoplasm
Dr. Priscilla A. Merriam
Hematology Oncology | Hematology | Oncology
Advanced in Splenic Neoplasm
Dr. Priscilla A. Merriam
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Priscilla Merriam is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Merriam is rated as an Elite provider by MediFind in the treatment of Splenic Neoplasm. Her top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, and Epithelioid Sarcoma. Dr. Merriam is currently accepting new patients.

Experienced in Splenic Neoplasm
Dr. Suzanne George
Oncology | Hematology
Experienced in Splenic Neoplasm
Dr. Suzanne George
Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Suzanne George is an Oncologist and a Hematologist in Boston, Massachusetts. Dr. George is rated as an Elite provider by MediFind in the treatment of Splenic Neoplasm. Her top areas of expertise are Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Liposarcoma, and Mesenchymoma. Dr. George is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Buchbinder's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile